263 related articles for article (PubMed ID: 31312712)
1. Checkpoint inhibitors in ovarian cancer: A review of preclinical data.
Doo DW; Norian LA; Arend RC
Gynecol Oncol Rep; 2019 Aug; 29():48-54. PubMed ID: 31312712
[TBL] [Abstract][Full Text] [Related]
2. Prospects for combining immune checkpoint blockade with PARP inhibition.
Li A; Yi M; Qin S; Chu Q; Luo S; Wu K
J Hematol Oncol; 2019 Sep; 12(1):98. PubMed ID: 31521196
[TBL] [Abstract][Full Text] [Related]
3. Combined Radiation Therapy and Immune Checkpoint Blockade Therapy for Breast Cancer.
Hu ZI; Ho AY; McArthur HL
Int J Radiat Oncol Biol Phys; 2017 Sep; 99(1):153-164. PubMed ID: 28816141
[TBL] [Abstract][Full Text] [Related]
4. Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery.
Colombo I; Karakasis K; Suku S; Oza AM
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370830
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint inhibition in ovarian cancer.
Hamanishi J; Mandai M; Konishi I
Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Higuchi T; Flies DB; Marjon NA; Mantia-Smaldone G; Ronner L; Gimotty PA; Adams SF
Cancer Immunol Res; 2015 Nov; 3(11):1257-68. PubMed ID: 26138335
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors.
Nero C; Ciccarone F; Pietragalla A; Duranti S; Daniele G; Salutari V; Carbone MV; Scambia G; Lorusso D
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803954
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors in Prostate Cancer.
Venkatachalam S; McFarland TR; Agarwal N; Swami U
Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34063238
[TBL] [Abstract][Full Text] [Related]
9. Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
Musacchio L; Cicala CM; Camarda F; Ghizzoni V; Giudice E; Carbone MV; Ricci C; Perri MT; Tronconi F; Gentile M; Salutari V; Scambia G; Lorusso D
ESMO Open; 2022 Aug; 7(4):100536. PubMed ID: 35849879
[TBL] [Abstract][Full Text] [Related]
10. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer.
Post CCB; Westermann AM; Bosse T; Creutzberg CL; Kroep JR
Crit Rev Oncol Hematol; 2020 Aug; 152():102973. PubMed ID: 32497971
[TBL] [Abstract][Full Text] [Related]
11. Driving Immune Responses in the Ovarian Tumor Microenvironment.
Ning F; Cole CB; Annunziata CM
Front Oncol; 2020; 10():604084. PubMed ID: 33520713
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs.
Drakes ML; Czerlanis CM; Stiff PJ
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33182298
[TBL] [Abstract][Full Text] [Related]
13. Ovarian cancer: new strategies and emerging targets for the treatment of patients with advanced disease.
Arend RC; Jackson-Fisher A; Jacobs IA; Chou J; Monk BJ
Cancer Biol Ther; 2021 Feb; 22(2):89-105. PubMed ID: 33427569
[TBL] [Abstract][Full Text] [Related]
14. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
15. Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.
Zhang G; Liu C; Bai H; Cao G; Cui R; Zhang Z
Oncol Lett; 2019 Mar; 17(3):2583-2591. PubMed ID: 30854033
[TBL] [Abstract][Full Text] [Related]
16. Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer.
Indini A; Nigro O; Lengyel CG; Ghidini M; Petrillo A; Lopez S; Raspagliesi F; Trapani D; Khakoo S; Bogani G
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916221
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in ovarian cancer: where do we stand?
Leary A; Tan D; Ledermann J
Ther Adv Med Oncol; 2021; 13():17588359211039899. PubMed ID: 34422119
[TBL] [Abstract][Full Text] [Related]
18. [Development of immune checkpoint inhibitors].
Kitano S
Rinsho Ketsueki; 2017; 58(8):966-976. PubMed ID: 28883282
[TBL] [Abstract][Full Text] [Related]
19. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
20. PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives.
Musacchio L; Caruso G; Pisano C; Cecere SC; Di Napoli M; Attademo L; Tambaro R; Russo D; Califano D; Palaia I; Muzii L; Benedetti Panici P; Pignata S
Cancer Manag Res; 2020; 12():6123-6135. PubMed ID: 32801862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
